ACCUTAR BIOTECHNOLOGY UNVEILS FIRST PATIENT DOSED IN CHINA WITH AC0682 IN PHASE 1 STUDY

KUALA LUMPUR, Oct 12 (Bernama) -- Accutar Biotechnology Inc has announced the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designed to target ERα protein with high potency and selectivity.

“The initiation of this study marks the first programme from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0682 Phase 1 study in the US late last year and the IND clearance by the China National Medical Products Administration (NMPA) earlier this year.

“Breast cancer is the most common cancer type among Chinese women. We look forward to accelerating the development of AC0682 globally with the goal of bringing transformative medicines to patients worldwide,” said Chief Executive Officer of Accutar Biotechnology Inc, Jie Fan, Ph.D.

According to a statement, the Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of AC0682 treatment in Chinese patients with ER-positive breast cancer.

Accutar Biotechnology Inc is a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery.

More details at www.accutarbio.com.

-- BERNAMA